General Information of the m6A Target Gene (ID: M6ATAR00084)
Target Name UBA6 divergent transcript (UBA6-DT/UBA6-AS1)
Synonyms
UBA6-DT; UBA6-AS1; UBA6 antisense RNA 1 (head to head); LOC550112
    Click to Show/Hide
Gene Name UBA6-DT
Chromosomal Location 4q13.2
Family Divergent transcripts
Gene ID 550112
HGNC ID
HGNC:49083
Ensembl Gene ID
ENSG00000248049
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
UBA6-DT can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
RNA-binding motif protein 15 (RBM15) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by RBM15
Cell Line Human BJ Fibroblast Homo sapiens
Treatment: siRBM15 BJ fibroblast
Control: siControl BJ fibroblast
GSE154148
Regulation
logFC: -3.20E+00
p-value: 2.22E-06
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary IGF2BP1 was identified as the m6A reader protein of UBA6 divergent transcript (UBA6-DT/UBA6-AS1)-RBM15-mediated m6A modification of UBA6 mRNA, which enhanced the stability of UBA6 mRNA. UBA6-AS1 suppressed the proliferation, migration and invasion of OC cells via UBA6.
Target Regulation Up regulation
Responsed Disease Ovarian cancer ICD-11: 2C73
In-vitro Model SK-OV-3 Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
OVCAR-3 Ovarian serous adenocarcinoma Homo sapiens CVCL_0465
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) [READER]
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary IGF2BP1 was identified as the m6A reader protein of UBA6 divergent transcript (UBA6-DT/UBA6-AS1)-RBM15-mediated m6A modification of UBA6 mRNA, which enhanced the stability of UBA6 mRNA. UBA6-AS1 suppressed the proliferation, migration and invasion of OC cells via UBA6.
Target Regulation Up regulation
Responsed Disease Ovarian cancer ICD-11: 2C73
In-vitro Model SK-OV-3 Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
OVCAR-3 Ovarian serous adenocarcinoma Homo sapiens CVCL_0465
Ovarian cancer [ICD-11: 2C73]
In total 3 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response []
Response Summary In ovarian cancer, a prognostic signature containing four LI-m6As (AC010894.3, ACAP2-IT1, CACNA1G-AS1, and UBA6 divergent transcript (UBA6-DT/UBA6-AS1)) was constructed according to the LASSO Cox regression analysis of the 10 LI-m6As.
Responsed Disease Ovarian cancer [ICD-11: 2C73]
Experiment 2 Reporting the m6A-centered Disease Response [1]
Response Summary IGF2BP1 was identified as the m6A reader protein of UBA6 divergent transcript (UBA6-DT/UBA6-AS1)-RBM15-mediated m6A modification of UBA6 mRNA, which enhanced the stability of UBA6 mRNA. UBA6-AS1 suppressed the proliferation, migration and invasion of OC cells via UBA6.
Responsed Disease Ovarian cancer [ICD-11: 2C73]
Target Regulator Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) READER
Target Regulation Up regulation
In-vitro Model SK-OV-3 Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
OVCAR-3 Ovarian serous adenocarcinoma Homo sapiens CVCL_0465
Experiment 3 Reporting the m6A-centered Disease Response [1]
Response Summary IGF2BP1 was identified as the m6A reader protein of UBA6 divergent transcript (UBA6-DT/UBA6-AS1)-RBM15-mediated m6A modification of UBA6 mRNA, which enhanced the stability of UBA6 mRNA. UBA6-AS1 suppressed the proliferation, migration and invasion of OC cells via UBA6.
Responsed Disease Ovarian cancer [ICD-11: 2C73]
Target Regulator RNA-binding motif protein 15 (RBM15) WRITER
Target Regulation Up regulation
In-vitro Model SK-OV-3 Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
OVCAR-3 Ovarian serous adenocarcinoma Homo sapiens CVCL_0465
References
Ref 1 Long noncoding RNA UBA6-AS1 inhibits the malignancy of ovarian cancer cells via suppressing the decay of UBA6 mRNA. Bioengineered. 2022 Jan;13(1):178-189. doi: 10.1080/21655979.2021.2011640.